Casdin Capital and Sofinnova Partners led a €75m Series A round in Mnemo Therapeutics.

Casdin Capital and Sofinnova Partners led a €75m Series A round in Mnemo Therapeutics, a biotechnology company, with participation from Redmile, Emerson Collective and Alexandria Venture Investments. "Mnemo Therapeutics is on an ambitious mission to transform the lives of patients made possible by the technological leadership of our scientific founders Dr. Sebastian Amigorena, CNRS researcher at Institut Curie and Dr. Michel Sadelain of Memorial Sloan Kettering Cancer Center. Based on the support from our premier investors and our team’s deep experience, we have completed a record-breaking Series A financing in France to develop powerful cell therapies that will achieve unprecedented breakthroughs for patients with solid and blood-based cancers," Alain Maiore, Mnemo Therapeutics CEO.